全文获取类型
收费全文 | 6666篇 |
免费 | 1154篇 |
国内免费 | 50篇 |
专业分类
耳鼻咽喉 | 74篇 |
儿科学 | 817篇 |
妇产科学 | 94篇 |
基础医学 | 406篇 |
口腔科学 | 97篇 |
临床医学 | 468篇 |
内科学 | 329篇 |
皮肤病学 | 59篇 |
神经病学 | 324篇 |
特种医学 | 153篇 |
外国民族医学 | 1篇 |
外科学 | 476篇 |
综合类 | 254篇 |
预防医学 | 331篇 |
眼科学 | 63篇 |
药学 | 211篇 |
11篇 | |
中国医学 | 40篇 |
肿瘤学 | 3662篇 |
出版年
2024年 | 6篇 |
2023年 | 269篇 |
2022年 | 172篇 |
2021年 | 422篇 |
2020年 | 548篇 |
2019年 | 645篇 |
2018年 | 627篇 |
2017年 | 501篇 |
2016年 | 288篇 |
2015年 | 391篇 |
2014年 | 462篇 |
2013年 | 770篇 |
2012年 | 352篇 |
2011年 | 364篇 |
2010年 | 300篇 |
2009年 | 307篇 |
2008年 | 299篇 |
2007年 | 213篇 |
2006年 | 189篇 |
2005年 | 104篇 |
2004年 | 84篇 |
2003年 | 63篇 |
2002年 | 51篇 |
2001年 | 47篇 |
2000年 | 37篇 |
1999年 | 43篇 |
1998年 | 33篇 |
1997年 | 31篇 |
1996年 | 24篇 |
1995年 | 22篇 |
1994年 | 24篇 |
1993年 | 22篇 |
1992年 | 20篇 |
1991年 | 15篇 |
1990年 | 8篇 |
1989年 | 11篇 |
1988年 | 11篇 |
1987年 | 6篇 |
1986年 | 8篇 |
1985年 | 14篇 |
1984年 | 14篇 |
1983年 | 13篇 |
1982年 | 8篇 |
1981年 | 3篇 |
1980年 | 9篇 |
1979年 | 5篇 |
1978年 | 5篇 |
1975年 | 2篇 |
1973年 | 2篇 |
1969年 | 2篇 |
排序方式: 共有7870条查询结果,搜索用时 15 毫秒
1.
Qing-Yang Que Lin-Cheng Zhang Jia-Qi Bao Sun-Bin Ling Xiao Xu 《World journal of gastrointestinal surgery》2022,14(5):397-408
Over the last 40 years, the incidence and prevalence of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) have continued to increase. Compared to other epithelial neoplasms in the same organ, GEP-NENs exhibit indolent biological behavior, resulting in more chances to undergo surgery. However, the role of surgery in high-grade or advanced GEP-NENs is still controversial. Surgery is associated with survival improvement of well-differentiated high-grade GEP-NENs, whereas poorly differentiated GEP-NENs that may benefit from resection require careful selection based on Ki67 and other tissue bio markers. Additionally, surgery also plays an important role in locally advanced and metastatic disease. For locally advanced GEP-NENs, isolated major vascular involvement is no longer an absolute contraindication. In the setting of metastatic GEP-NENs, radical intended surgery is recommended for patients with low-grade and resectable metastases. For unresectable metastatic disease, a variety of surgical approaches, including cytoreduction of liver metastasis, liver transplantation, and surgery after neoadjuvant treatment, show survival benefits. Primary tumor resection in GEP-NENs with unresectable metastatic disease is associated with symptom control, prolonged survival, and improved sensitivity toward systemic therapies. Although there is no established neoadjuvant or adjuvant strategy, increasing attention has been given to this emerging research area. Some studies have reported that neoadjuvant therapy effectively reduces tumor burden, improves the effectiveness of subsequent surgery, and decreases surgical complications. 相似文献
2.
Raymond J. Chan RN PhD Vivienne E. Milch MBBS MHPol Fiona Crawford-Williams PhD Oluwaseyifunmi Andi Agbejule BRadTherapy Ria Joseph MNutrDiet Jolyn Johal BND Narayanee Dick BSc Matthew P. Wallen PhD Julie Ratcliffe PhD Anupriya Agarwal MBBS Larissa Nekhlyudov MD Matthew Tieu PhD Manaf Al-Momani BPharm Scott Turnbull PhD Rahul Sathiaraj MPH Dorothy Keefe MBBS MD Nicolas H. Hart PhD 《CA: a cancer journal for clinicians》2023,73(6):565-589
Patient navigation is a strategy for overcoming barriers to reduce disparities and to improve access and outcomes. The aim of this umbrella review was to identify, critically appraise, synthesize, and present the best available evidence to inform policy and planning regarding patient navigation across the cancer continuum. Systematic reviews examining navigation in cancer care were identified in the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Embase, Cumulative Index of Nursing and Allied Health (CINAHL), Epistemonikos, and Prospective Register of Systematic Reviews (PROSPERO) databases and in the gray literature from January 1, 2012, to April 19, 2022. Data were screened, extracted, and appraised independently by two authors. The JBI Critical Appraisal Checklist for Systematic Review and Research Syntheses was used for quality appraisal. Emerging literature up to May 25, 2022, was also explored to capture primary research published beyond the coverage of included systematic reviews. Of the 2062 unique records identified, 61 systematic reviews were included. Fifty-four reviews were quantitative or mixed-methods reviews, reporting on the effectiveness of cancer patient navigation, including 12 reviews reporting costs or cost-effectiveness outcomes. Seven qualitative reviews explored navigation needs, barriers, and experiences. In addition, 53 primary studies published since 2021 were included. Patient navigation is effective in improving participation in cancer screening and reducing the time from screening to diagnosis and from diagnosis to treatment initiation. Emerging evidence suggests that patient navigation improves quality of life and patient satisfaction with care in the survivorship phase and reduces hospital readmission in the active treatment and survivorship care phases. Palliative care data were extremely limited. Economic evaluations from the United States suggest the potential cost-effectiveness of navigation in screening programs. 相似文献
3.
4.
5.
6.
7.
8.
Monika Scheer Christian Vokuhl Iris Veit‐Friedrich Marc Münter Thekla von Kalle Michael Greulich Steffan Loff Sabine Stegmaier Monika Sparber‐Sauer Felix Niggli Ruth Ladenstein Bernarda Kazanowska Gustaf Ljungman Kirsi Jahnukainen Jrg Fuchs Stefan S. Bielack Ewa Koscielniak Thomas Klingebiel 《Pediatric blood & cancer》2020,67(2)
9.
10.
Katja Kobow Christopher A. Reid Erwin A. van Vliet Albert J. Becker Gemma L. Carvill Alica M. Goldman Shinichi Hirose Iscia Lopes-Cendes Hela Mrabet Khiari Annapurna Poduri Michael R. Johnson David C. Henshall 《Epileptic Disord》2020,22(2):127-141
Epigenetics refers broadly to processes that influence medium to long‐term gene expression by changing the readability and accessibility of the genetic code. The Neurobiology Commission of the International League Against Epilepsy (ILAE) recently convened a Task Force to explore and disseminate advances in epigenetics to better understand their role and intersection with genetics and the neurobiology of epilepsies and their co‐morbidities, and to accelerate translation of these findings into the development of better therapies. Here, we provide a topic primer on epigenetics, explaining the key processes and findings to date in experimental and human epilepsy. We review the growing list of genes with epigenetic functions that have been linked with epilepsy in humans. We consider potential practical applications, including using epigenetic signals as biomarkers for tissue‐ and biofluid‐based diagnostics and the prospects for developing epigenetic‐based treatments for epilepsy. We include a glossary of terms, FAQs and other supports to facilitate a broad understanding of the topic for the non‐expert. Last, we review the limitations, research gaps and the next challenges. In summary, epigenetic processes represent important mechanisms controlling the activity of genes, providing opportunities for insight into disease mechanisms, biomarkers and novel therapies for epilepsy. 相似文献